Piper longum L. (family Piperaceae), known as Pippali in Sanskrit and long pepper in English, is an established Ayurvedic drug prepared from the dried, immature, catkin-like fruits of the plant. Modern pharmacology often describes its alkaloid piperine as a bioenhancer. This term refers to measured changes in exposure to particular co-administered compounds; it does not make Pippali a universal carrier of all herbs or medicines. The whole fruit used in Ayurveda must also be distinguished from concentrated piperine extracts used in supplements and pharmacokinetic experiments.

Ayurvedic Identity and Dravyaguna

The Ayurvedic Pharmacopoeia of India describes Pippali with katu rasa; laghu and snigdha guna; anushna virya; and madhura vipaka. Its listed actions include dipana, ruchya, kaphahara, vatahara, tridoshahara, rasayana, vrishya, and rechana. These official attributes are more precise than descriptions that label Pippali simply as hot, pungent, and universally absorption-enhancing.

The pharmacopoeial monograph lists uses that include kasa, shvasa, hikka, jvara, ama-vata, arsha, gulma, krimi, pliha-roga, and udara-roga. These Sanskrit indications belong to the Ayurvedic diagnostic framework and should not automatically be treated as exact equivalents of modern disease names. The API dose for the fruit is 1–3 g, while India’s National List of Essential AYUSH Medicines gives 1–2 g for Pippali Churna and cautions against long-term use in higher doses.

Piperine and Pharmacokinetic Mechanisms

Piperine is an alkaloid occurring in Piper longum and Piper nigrum. Its concentration varies with the species, plant material, origin, and analytical method, so a fixed piperine percentage should not be assumed for every Pippali powder. Laboratory experiments using human Caco-2 intestinal cells and human liver microsomes found that piperine inhibited P-glycoprotein-mediated transport and CYP3A4 activity. Other experimental work found that piperine can modify intestinal glucuronidation, a conjugation pathway involved in the metabolism of several compounds.

These mechanisms may increase, decrease, or leave unchanged the exposure of a co-administered substance, depending on its dose, formulation, metabolic pathway, and study setting. The most directly demonstrated mechanisms include modulation of drug-metabolizing enzymes, efflux transport, and glucuronidation.

The Curcumin–Piperine Study

In a 1998 human pharmacokinetic experiment, 2 g of curcumin given with 20 mg of piperine produced a reported 2000% increase in relative bioavailability compared with curcumin alone. The paper associated this effect with piperine’s inhibition of hepatic and intestinal glucuronidation. The result applies to the doses and preparations tested; it does not establish that every curcumin product or every Pippali-containing formula will produce the same twenty-fold change.

Human Bioavailability Findings

Human findings differ substantially among compounds. Coenzyme Q10 and beta-carotene trials reported increased systemic exposure with 5 mg of isolated piperine, whereas a later resveratrol pilot did not reproduce the enhancement previously observed in mice. Pharmacokinetic results must therefore be interpreted separately for each substance and formulation.

Co-administered Compound Study Setting Piperine Dose Verified Finding Reference
Curcumin Human pharmacokinetic study 20 mg with 2 g curcumin 2000% increase in relative bioavailability PMID 9619120
Coenzyme Q10 Healthy adult men, 21-day supplementation 5 mg with 120 mg CoQ10 Approximately 30% greater plasma AUC PMID 10715596
Beta-carotene 12 healthy men, crossover study 5 mg with 15 mg beta-carotene 60% greater serum beta-carotene AUC DOI 10.1016/S0271-5317(99)00007-X
Resveratrol 24-person randomized pilot 5 or 25 mg with 2.5 g resveratrol No significant dose–pharmacokinetic relationship PMID 32868637
PIPERINE: VERIFIED PHARMACOKINETIC CONSIDERATIONS
1
Glucuronidation Modulation
Experimental work demonstrates altered intestinal glucuronidation, a mechanism relevant to the curcumin finding.

2
CYP3A4 Inhibition
Human liver-microsome experiments found inhibition of CYP3A4-mediated metabolism.

3
P-gp Efflux Inhibition
A human intestinal cell model found inhibition of the P-glycoprotein efflux transporter.

These mechanisms concern isolated piperine and do not predict a uniform effect for every nutrient, herb, or prescription medicine.

Trikatu and Formulation Context

Trikatu Churna combines Pippali fruit, Maricha (Piper nigrum) fruit, and Shunthi (Zingiber officinale) rhizome in equal proportions. The National List of Essential AYUSH Medicines identifies Trikatu as an Ayurvedic Formulary of India medicine for arochaka, ama, and agnimandya, with a listed dose of 1–2 g. It also records precautions for paittika vikara or prakriti, raktaja roga, pregnancy, and long-term use. Its Ayurvedic purpose is therefore broader and more formulation-specific than the modern label “bioavailability enhancer.”

Respiratory and Rasayana Context

Pippali’s official Ayurvedic indications include kasa and shvasa, and Pippali Churna is listed for rasayana, jvara, shvasa, and kasa. This supports its traditional respiratory and rejuvenative context without assigning it a special respiratory prabhava or equating the Sanskrit terms with asthma, bronchitis, or another single biomedical diagnosis. Classical use does not replace examination and treatment of persistent cough, wheezing, fever, breathlessness, or suspected infection.

Constituents Beyond Piperine

Piper longum also contains piperlongumine, which is the same compound as piplartine rather than a separate alkaloid. Piperlongumine has produced preferential toxicity toward cancer cells and increased reactive oxygen species in cell-based and animal models. These are preclinical observations; piperlongumine is not an established cancer treatment, and Pippali should not be promoted as a substitute for oncology care.

Safety and Drug Interactions

Piperine’s effects on metabolism and transport create a meaningful interaction concern with medicines. Human experiments have reported altered pharmacokinetics of phenytoin, propranolol, and theophylline when piperine was co-administered. Particular caution is appropriate with medicines that require stable blood concentrations or have a narrow therapeutic index. Culinary pepper exposure is not equivalent to a concentrated piperine capsule, and the safety of an isolated bolus supplement cannot be inferred solely from ordinary food use.

Use Pippali and Trikatu in doses, durations, and combinations selected for the individual rather than as unrestricted daily “absorption boosters.” During pregnancy, and for children, older adults, people with liver or kidney disease, or anyone taking prescription medicines, consult a qualified Ayurvedic practitioner and a healthcare provider or pharmacist before medicinal use. New or worsening respiratory, gastrointestinal, neurological, or allergic symptoms require appropriate medical assessment.

Pippali is best understood through both frameworks without forcing them into equivalence: Ayurveda defines the fruit by its authenticated identity, rasa-guna-virya-vipaka, actions, indications, formulations, and dose, while pharmacology evaluates isolated constituents under specified experimental conditions. Piperine can alter exposure to selected compounds, but the effect is neither universal nor automatically beneficial.

References

  1. Ayurvedic Pharmacopoeia of India
  2. Upayushsociety (upayushsociety.com)
  3. Nopr (nopr.niscpr.res.in)
  4. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 (2002), PubMed
  5. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogeneous UDP-glucuronic acid content (1986), PubMed
  6. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers (1998), PubMed
  7. Piperine derived from black pepper increases the plasma levels of coenzyme Q10 following oral supplementation (2000), PubMed
  8. DOI: 10.1016/S0271-5317(99
  9. Enhancing the bioavailability of resveratrol by combining it with piperine (2011), PubMed
  10. A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol (2021), PubMed
  11. Piperlongumine (piplartine) as a lead compound for anticancer agents – Synthesis and properties of analogues: A mini-review (2018), PubMed
  12. Selective killing of cancer cells by a small molecule targeting the stress response to ROS (2011), PubMed
  13. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy (2006), PubMed
  14. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers (1991), PubMed
  15. Safety Aspects of the Use of Isolated Piperine Ingested as a Bolus (2021), PubMed Central